The Zacks Analyst Blog Highlights: Myriad Genetics, Anika Therapeutics, Biogen Idec , Alexion Pharmaceuticals and …

Posted: June 18, 2013 at 5:48 pm

For Immediate Release

Chicago, IL June 18, 2013 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Myriad Genetics Inc. (MYGN-Free Report), Anika Therapeutics Inc. (ANIK-Free Report), Biogen Idec Inc. (BIIB-Free Report), Alexion Pharmaceuticals, Inc. (ALXN-Free Report) and Cabot Oil & Gas Corporation (COG-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Mondays Analyst Blog:

Myriad: End to Legal Battle Over Patents

The much hyped Supreme Court ruling regarding legal claims that challenge its patent landscape is out for Myriad Genetics Inc. (MYGN-Free Report) and it seems like a halfway triumph for this molecular diagnostic company.

The Issue

In Nov 2012, Myriad revealed that the U.S. Supreme Court would review the decision of U.S. Court of Appeals for the Federal Circuit. It applies to the companys composition of matter claims that isolated DNA of the BRCA1 and BRCA2 genes are patentable. Earlier, in Apr 2012, U.S. Court of Appeals for the Federal Circuit declared that Myriads composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes were patentable.

Following the Supreme Court review, earlier ruling by the Federal Circuit Court of Appeals to declare the patentability of Myriads composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes were subject to legal scrutiny once again. The legal claims pertain to the companys flagship Bracanalysis test. The decision was anticipated in Jun 2013.

The Verdict

Read more:
The Zacks Analyst Blog Highlights: Myriad Genetics, Anika Therapeutics, Biogen Idec , Alexion Pharmaceuticals and ...

Related Posts

Comments are closed.

Archives